Duration of antifungal therapy for septic pulmonary embolism caused by Candida albicans from a central venous catheter: A case report

The treatment duration for candidemia with septic pulmonary embolism should be determined based on the clearance of fungus from the bloodstream and improvement of symptoms. The remaining lung nodules may not necessarily indicate persistent infection.

[1]  Jin-liang Kong,et al.  Septic pulmonary embolism in China: clinical features and analysis of prognostic factors for mortality in 98 cases , 2019, BMC Infectious Diseases.

[2]  Rachel M. Kenney,et al.  T2 Candida versus beta-D-glucan to facilitate antifungal discontinuation in the intensive care unit. , 2019, Diagnostic microbiology and infectious disease.

[3]  B. Kullberg,et al.  Invasive Candidiasis. , 2019, The New England journal of medicine.

[4]  I. Raad,et al.  Appropriate Duration of Intravenous Treatment of Candidemia and Timing of Step Down to Oral Therapy in Non-neutropenic Patients , 2018, Mediterranean journal of hematology and infectious diseases.

[5]  Rui Xia,et al.  Evaluation of candidemia in epidemiology and risk factors among cancer patients in a cancer center of China: an 8-year case-control study , 2017, BMC Infectious Diseases.

[6]  J. Sobel,et al.  Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  J. Sobel,et al.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  C. Clancy,et al.  Finding the "missing 50%" of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  G. Fadda,et al.  Biofilm Production by Candida Species and Inadequate Antifungal Therapy as Predictors of Mortality for Patients with Candidemia , 2007, Journal of Clinical Microbiology.

[10]  K. Garey,et al.  Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  Victoria J. Fraser,et al.  Delaying the Empiric Treatment of Candida Bloodstream Infection until Positive Blood Culture Results Are Obtained: a Potential Risk Factor for Hospital Mortality , 2005, Antimicrobial Agents and Chemotherapy.

[12]  G. Aughenbaugh,et al.  Septic pulmonary embolism: presenting features and clinical course of 14 patients. , 2005, Chest.

[13]  S. Fridkin,et al.  Epidemiology and Predictors of Mortality in Cases of Candida Bloodstream Infection: Results from Population-Based Surveillance, Barcelona, Spain, from 2002 to 2003 , 2005, Journal of Clinical Microbiology.

[14]  B. Kullberg,et al.  Invasive Candidiasis. , 2015, The New England journal of medicine.

[15]  R. Ye,et al.  Clinical characteristics of septic pulmonary embolism in adults: a systematic review. , 2014, Respiratory medicine.